INTRODUCTION
For five decades, the oncology pharmaceuticals market has been dominated by cytotoxic therapies, used alone or in combinations. In 2002, however,
this dominance began to be challenged by improved molecular biology techniques and the niche positioning of biotechnology companies specializing in
rational drug design.
SCOPE OF THE REPORT
- Discussion of the role niche cancers are assuming in the oncology market as of 2002
- Strategy-oriented discussion of lifecycle strategies being employed by selected maturing or emerging high-profile oncology drugs
- Predictions for changes in the clinical trials design process to accommodate the mechanism of action of novel molecular-based products
REPORT HIGHLIGHTS
Niche cancers are beginning to receive as much attention for new drug development as has long been enjoyed by major cancers, with indications such
as leukemia and multiple myeloma attracting investment and research resources
Aggressive marketing can extend the lifespan of commercialized agents, but competition from generics and replacement products means that few drugs
can maintain blockbuster sales in the oncology field for more than a few years, based on the experiences of 2002
Pipeline agents from novel classes are eagerly awaited but face the challenges of proving themselves more effective than a plethora of established
agents, despite difficulties in clinical trial design
KEY REASONS TO BUY THIS REPORT
- Identify market trends from 2002, and predict their impact on the market in 2003
- Understand the importance of niche cancers in the development of oncology portfolios
- Track the development of clinical trial design, as novel drugs enter clinical trials
View Cart
